GLP-1 Microdosing: The Complete
Dosing Chart & What the Data Says

If you have been researching GLP-1 medications online, you have almost certainly come across the term “microdosing.” It sounds appealing: all the benefits of semaglutide or tirzepatide, but at a lower dose, with fewer side effects, and at a lower cost. Platforms like Noom have built entire product lines around it. Social media is full of people swearing by their 0.1mg weekly injections.

But what does the clinical evidence actually say? Is microdosing a legitimate medical strategy, a clever marketing term, or something in between? The answer, as with most things in medicine, is complicated.

What Is GLP-1 Microdosing?

In the context of weight loss, “microdosing” refers to using GLP-1 medications at doses significantly lower than the standard FDA-approved clinical doses. The FDA-approved starting dose for semaglutide (Wegovy) is 0.25mg weekly, escalating over several months to a maintenance dose of 2.4mg weekly. Microdosing typically means staying well below that ceiling — often in the 0.05mg to 0.6mg range — either indefinitely or as a slower, more gradual titration approach.

There are two distinct use cases that get lumped under the “microdosing” umbrella, and it is important to distinguish them:

1. Slow titration microdosing — Starting at a very low dose (e.g., 0.05mg weekly) and escalating more slowly than the standard protocol. The goal is to eventually reach standard therapeutic doses, but with a gentler on-ramp that minimizes side effects. This is a clinically sound approach with good medical rationale.

2. Maintenance microdosing — Staying permanently at a low dose (e.g., 0.5-0.6mg) rather than escalating to the full clinical dose. This is the more controversial approach, and the one that platforms like Noom have commercialized.

The Dosing Charts: Microdose vs. Standard Protocol

The two charts below tell the essential story. On the left, you can see how a standard Wegovy titration schedule compares to a typical microdose protocol over 24 weeks. On the right, you can see the approximate weight loss outcomes at different dose levels based on available clinical data.

The Standard Microdosing Schedule

There is no single universally agreed-upon microdosing protocol. Different telehealth platforms and compounding pharmacies use different schedules. However, the most commonly cited approach for a slow-titration microdose protocol looks like this:

Compare this to the standard Wegovy protocol, which reaches 2.4mg weekly by week 17 and produces an average of 15-16% body weight loss over 68 weeks in clinical trials.

What the Clinical Data Actually Shows

Here is where the honest conversation gets uncomfortable for microdosing advocates.

GLP-1 weight loss is dose-dependent. This is one of the most consistent findings across every major clinical trial. The more semaglutide you take (up to the maximum approved dose), the more weight you lose. The STEP trials showed that patients on 2.4mg lost an average of 15-16% of body weight. Patients on 1.0mg (the Ozempic dose) lost approximately 8-9%. Patients on 0.5mg lost approximately 6%.

There is no published clinical trial specifically studying maintenance microdosing at 0.1-0.3mg for weight loss. The data that exists for these very low doses comes from titration phases of larger trials, where patients are only at those doses for 4 weeks before escalating. The weight loss observed during these titration phases is minimal — typically 1-3% of body weight.

One frequently cited piece of evidence for microdosing comes from a Noom-sponsored study that found patients taking just 1mg of semaglutide lost an average of 16% of body weight over 64 weeks — nearly matching the 2.4mg Wegovy results. This is genuinely interesting data. But 1mg is not what most people mean when they say “microdosing.” It is still four times higher than the 0.25mg starting dose and well above the 0.6mg ceiling that Noom’s own Microdose product caps at.

When Microdosing Makes Sense

Despite the limitations on efficacy at very low doses, there are legitimate clinical reasons to use a microdosing approach. Here are the scenarios where it genuinely makes sense.

1. You Are Highly Sensitive to GLP-1 Side Effects

Some patients experience severe nausea, vomiting, or gastrointestinal distress even at the standard 0.25mg starting dose. For these patients, starting at 0.05mg or 0.1mg and escalating extremely slowly is a medically sound strategy. The goal is still to reach a therapeutic dose — it just takes longer to get there.

2. You Only Have a Small Amount of Weight to Lose

If your goal is to lose 10-15 pounds rather than 50+, a lower maintenance dose may be sufficient to achieve and maintain your target weight. The dose-response relationship means you need less medication to achieve a modest goal than a large one.

3. You Are Using GLP-1 for Non-Weight Purposes

Emerging research suggests GLP-1 medications may have benefits beyond weight loss — including potential effects on addiction, anxiety, and inflammation — at doses lower than those needed for significant weight loss. This is an active area of research, but it is one reason some patients and providers explore lower doses for reasons other than the number on the scale.

4. You Are Transitioning Off Full-Dose Therapy

Rather than stopping GLP-1 medications abruptly (which typically leads to rapid weight regain), some providers use a gradual dose reduction strategy — essentially microdosing on the way down — to help patients maintain their results while building sustainable lifestyle habits.

The Microdosing Marketing Problem

It is worth being direct about something: the explosion of “microdosing” as a consumer concept is partly a marketing phenomenon driven by the regulatory and legal pressure on compounded GLP-1 providers.

When the FDA moved to restrict compounded semaglutide in early 2026, platforms that had built their business on cheap compounded drugs needed a new angle. Microdosing — which uses less active ingredient per dose, is cheaper to produce, and sidesteps some of the regulatory scrutiny around standard-dose compounding — became that angle. The marketing is clever: “fewer side effects,” “more sustainable,” “work with your body’s natural rhythms.”

None of these claims are necessarily false. But they can obscure the fundamental reality that at doses below 0.5mg, most patients will not lose meaningful weight. If you are paying $199/month for a microdose program and not seeing results after 3-4 months, the dose is almost certainly the reason.

Our Verdict on GLP-1 Microdosing

Microdosing as a titration strategy — starting low and escalating slowly to minimize side effects — is clinically sound and widely recommended. If you are sensitive to GLP-1 medications, there is no reason to rush the standard titration schedule.

Microdosing as a permanent maintenance strategy at doses below 0.5mg is a different matter. The clinical evidence does not support meaningful weight loss at these doses for most patients. If a platform is selling you a “microdose program” capped at 0.3mg or 0.6mg as a complete weight loss solution, you should ask hard questions about what results you can realistically expect.

The best approach: work with a qualified provider who will start you at a low dose to minimize side effects, but who has a clear plan to escalate you to a therapeutically effective dose over time. That is not microdosing — that is just good medicine.